

## Sunesis Pharmaceuticals to Report First Quarter 2007 Financial Results

April 27, 2007 1:16 PM ET

SOUTH SAN FRANCISCO, Calif., April 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Friday, May 4, 2007 at 10:00 a.m. ET/7:00 a.m. PT to discuss financial results for the fourth quarter and fiscal year 2006.

Individual and institutional investors can access the call via (800) 289-0438 (U.S. and Canada) or (913) 981-5527 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at <http://www.sunesis.com>. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

### About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of targeted cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit <http://www.sunesis.com>.

### Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.

### SOURCE Sunesis Pharmaceuticals, Inc.

Investors, Eric Bjerkholt, SVP, Corp. Development and Finance of Sunesis Pharmaceuticals, Inc., +1-650-266-3717, or media, Michelle Corral of BCC Partners, +1-650-575-1509 or +1-415-794-8662

<http://www.sunesis.com>

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX